Reports Q4 revenue $196M, consensus $193.26M. “Our fourth quarter and full year 2025 results demonstrate strong commercial momentum across our marketed products, and advancement and expansion of our innovative CNS pipeline, which now includes five differentiated product candidates,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics (AXSM). “2026 promises to be another eventful year for Axsome with continued commercial execution, and multiple regulatory and clinical milestones including potential FDA action on our sNDA for AXS-05 in Alzheimer’s disease agitation, NDA filing for AXS-12 in narcolepsy, and clinical trial progress across our development portfolio.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Options Volatility and Implied Earnings Moves Today, February 23, 2026
- AXSM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Axsome Therapeutics price target raised to $230 from $217 at Mizuho
- Axsome Therapeutics: Strengthened Sunosi Exclusivity and Robust Late‑Stage Pipeline Underpin Buy Rating
- Axsome secures long-term SUNOSI exclusivity through Alkem settlement